View Older Stories

Jan 20, 2026 07:00AM Viatris launches heart failure drug Inpefa in UAE

Dec 10, 2025 08:31AM Lexicon publishes preclinical data supporting LX9851 obesity treatment

Nov 10, 2025 02:33AM Lexicon presents sotagliflozin data for heart failure patients without diabetes

Nov 6, 2025 07:59AM Lexicon Pharma (LXRX) Tops Q3 EPS by 3c

Oct 14, 2025 08:01AM Lexicon presents additional pilavapadin data for diabetic nerve pain

Sep 22, 2025 04:00PM Lexicon submits additional data to FDA for Zynquista diabetes drug review

Sep 11, 2025 06:50AM H.C. Wainwright Reiterates Buy Rating on Lexicon Pharmaceuticals (LXRX)

Sep 9, 2025 06:50AM H.C. Wainwright Reiterates Buy Rating on Lexicon Pharmaceuticals (LXRX)

Sep 8, 2025 08:31AM Lexicon submits additional data to FDA for Zynquista diabetes drug

Sep 3, 2025 06:50AM H.C. Wainwright Reiterates Buy Rating on Lexicon Pharmaceuticals (LXRX)

Sep 2, 2025 08:33AM Lexicon's sotagliflozin shows consistent heart failure benefits across age groups

Aug 7, 2025 08:09AM Lexicon Pharma (LXRX) PT Raised to $1.90 at Citi, Adds 90d Upside Catalyst Watch

Aug 6, 2025 12:06PM Lexicon Pharmaceuticals (LXRX) PT Raised to $0.85 at Jefferies

Aug 6, 2025 07:32AM Lexicon Pharma (LXRX) Tops Q2 EPS by 10c

Jun 24, 2025 06:52AM H.C. Wainwright Reiterates Buy Rating on Lexicon Pharmaceuticals (LXRX)

May 13, 2025 04:01PM Lexicon Pharma (LXRX) Tops Q1 EPS by 5c

Apr 2, 2025 08:01AM Lexicon Pharma (LXRX) to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 31, 2025 06:46AM H.C. Wainwright Reiterates Buy Rating on Lexicon Pharmaceuticals (LXRX)

Mar 28, 2025 07:30AM Lexicon Pharma (LXRX) Announces Exclusive License Agreement with Novo Nordisk for LX9851

Mar 6, 2025 04:01PM Lexicon Pharma (LXRX) Tops Q4 EPS by 3c

Mar 4, 2025 06:46AM H.C. Wainwright Reiterates Buy Rating on Lexicon Pharmaceuticals (LXRX)

Mar 3, 2025 07:01AM Lexicon Pharma (LXRX) Announces Topline Results from Phase 2b PROGRESS Study

Jan 3, 2025 08:23AM Piper Sandler Explores Direct and Indirect Catalysts for Selected Biotechnology Companies

Jan 2, 2025 08:04AM Lexicon Pharma (LXRX) Appoints Scott Coiante as CFO

Dec 12, 2024 06:47AM H.C. Wainwright Reiterates Buy Rating on Lexicon Pharmaceuticals (LXRX)

Nov 25, 2024 06:39AM Lexicon Pharmaceuticals (LXRX) PT Lowered to $4 at H.C. Wainwright

Nov 22, 2024 07:33AM Lexicon Pharma (LXRX) to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA

Nov 20, 2024 04:06PM Lexicon Pharma (LXRX) Appoints Ivan H. Cheung to its Board

Nov 12, 2024 04:10PM Lexicon Pharma (LXRX) Misses Q3 EPS by 2c

Nov 12, 2024 04:05PM Lexicon Pharma (LXRX) Misses Q3 EPS by 2c

Nov 1, 2024 07:22AM Lexicon Pharmaceuticals (LXRX) PT Lowered to $5 at Leerink Partners

Nov 1, 2024 06:40AM Lexicon Pharmaceuticals (LXRX) PT Lowered to $6 at H.C. Wainwright

Oct 31, 2024 07:01AM Lexicon Pharma (LXRX) Halted, News Pending

Oct 23, 2024 09:05AM Lexicon Pharma (LXRX): New Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to be Presented at ASN

Oct 18, 2024 05:48AM Lexicon Pharmaceuticals (LXRX) PT Raised to $6 at Leerink Partners

Oct 17, 2024 07:53AM Piper Sandler Reiterates Overweight Rating on Lexicon Pharmaceuticals (LXRX)

Oct 17, 2024 06:55AM H.C. Wainwright Reiterates Buy Rating on Lexicon Pharmaceuticals (LXRX)

Oct 16, 2024 04:35PM Lexicon Pharma (LXRX) Announces Exclusive Licensing Agreement With Viatris (VTRS) for Sotagliflozin in All Markets Outside of the U.S. and Europe

Oct 10, 2024 07:40AM Piper Sandler Reiterates Overweight Rating on Lexicon Pharmaceuticals (LXRX)

Oct 3, 2024 06:57AM H.C. Wainwright Reiterates Buy Rating on Lexicon Pharmaceuticals (LXRX)

Sep 30, 2024 07:26AM H.C. Wainwright Reiterates Buy Rating on Lexicon Pharmaceuticals (LXRX)

Sep 16, 2024 06:57AM Lexicon Pharma (LXRX) Announces COO Departuree

Sep 11, 2024 06:38AM H.C. Wainwright Reiterates Buy Rating on Lexicon Pharmaceuticals (LXRX)

Sep 10, 2024 08:04AM Lexicon Pharma (LXRX): New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves TIR and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes

Sep 7, 2024 08:00PM Here's the list of biotech stocks that have key data catalysts in 2025

Aug 21, 2024 08:02AM Lexicon Pharma (LXRX) Announces FDA AdCom Meeting for Zynquista

Aug 13, 2024 08:32AM Lexicon Pharma (LXRX) Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio

Aug 1, 2024 04:04PM Lexicon Pharma (LXRX) Tops Q2 EPS by 1c

Jul 16, 2024 09:15AM Piper Sandler Reiterates Overweight Rating on Lexicon Pharmaceuticals (LXRX)

Jul 16, 2024 08:03AM Lexicon Pharma (LXRX) Receives December 20, 2024 PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission

View Older Stories